| 13.44 0.06 (0.45%) | 01-30 15:51 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 15.96 | 1-year : | 18.64 |
| Resists | First : | 13.67 | Second : | 15.96 |
| Pivot price | 12.65  |
|||
| Supports | First : | 12.02 | Second : | 11.01 |
| MAs | MA(5) : | 13.34 |
MA(20) : | 12.44 |
| MA(100) : | 10.73 |
MA(250) : | 9.84  |
|
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 78.7 |
D(3) : | 82.1 |
| RSI | RSI(14): 62.7 |
|||
| 52-week | High : | 20.37 | Low : | 5.9 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ARVN ] has closed below upper band by 12.1%. Bollinger Bands are 17.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 13.42 - 13.47 | 13.47 - 13.52 |
| Low: | 12.63 - 12.69 | 12.69 - 12.75 |
| Close: | 13.27 - 13.37 | 13.37 - 13.47 |
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Wed, 28 Jan 2026
Y Intercept Hong Kong Ltd Buys 137,794 Shares of Arvinas, Inc. $ARVN - MarketBeat
Tue, 27 Jan 2026
There Is A Reason Arvinas, Inc.'s (NASDAQ:ARVN) Price Is Undemanding - 富途牛牛
Tue, 27 Jan 2026
Companies Like Arvinas (NASDAQ:ARVN) Are In A Position To Invest In Growth - Sahm
Fri, 23 Jan 2026
Arvinas, Inc. (ARVN) Stock Analysis: Navigating The Biotech Frontier With Potential Upside - DirectorsTalk Interviews
Sun, 18 Jan 2026
Nordea Investment Management AB Grows Position in Arvinas, Inc. $ARVN - MarketBeat
Sat, 17 Jan 2026
Arvinas, Inc. $ARVN Stock Position Boosted by Campbell & CO Investment Adviser LLC - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 64 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 7.8 (%) |
| Held by Institutions | 96.2 (%) |
| Shares Short | 4,860 (K) |
| Shares Short P.Month | 6,480 (K) |
| EPS | -0.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.96 |
| Profit Margin | -18.8 % |
| Operating Margin | -105.1 % |
| Return on Assets (ttm) | -6.4 % |
| Return on Equity (ttm) | -10.2 % |
| Qtrly Rev. Growth | -59.1 % |
| Gross Profit (p.s.) | 4.86 |
| Sales Per Share | 4.86 |
| EBITDA (p.s.) | -1.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -328 (M) |
| Levered Free Cash Flow | -135 (M) |
| PE Ratio | -16.65 |
| PEG Ratio | 0 |
| Price to Book value | 1.69 |
| Price to Sales | 2.77 |
| Price to Cash Flow | -2.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |